Hansa Biopharma AB (HNSA) — Cash Flow Reinvestment Rate
Latest as of September 2020:
3.23x
Hansa Biopharma AB (HNSA) has a Cash Flow Reinvestment Rate of 3.23x as of September 2020, reinvesting Skr15.60 Million (capex Skr683.00K plus investments Skr14.91 Million) from operating cash flow of Skr4.83 Million. Explore Hansa Biopharma AB operating cash flow efficiency to assess how effectively this company generates cash.
Reinvestment Rate
3.23x
(Capex + Investments) / Operating CF
Total Reinvested
Skr15.60 Million
Capex + Investments
Operating Cash Flow
Skr4.83 Million
SEK
Capital Expenditures
Skr683.00K
SEK
Annual Cash Flow Reinvestment Rate for Hansa Biopharma AB (None–None)
Year-by-year capital reinvestment analysis for Hansa Biopharma AB. For live market cap and broader valuation context, see how much is Hansa Biopharma AB worth.
| Year | Reinvestment Rate | Total Reinvested (SEK) | Operating CF | Capex | YoY Change |
|---|
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow